Sun Pharma completes acquisition of Concert Pharmaceuticals

The drug major has successfully completed the acquisition of Concert Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company that is developing deuruxolitinib for the potential treatment of adult patients with moderate to severe alopecia areata, Sun Pharma said in a regulatory filing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/YVgFSaA
via IFTTT